Basit öğe kaydını göster

dc.contributor.authorAcik, Didar Yanardag
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorUlas, Turgay
dc.contributor.authorOzet, Gulsum
dc.contributor.authorFerhanoglu, Burhan
dc.contributor.authorNalcaci, Meliha
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorUlu, Bahar Uncu
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorMEHTAP, ÖZGÜR
dc.contributor.authorBuyukkurt, Nurhilal
dc.contributor.authorHindilerden, Fehmi
dc.contributor.authorGunes, Ahmet Kursad
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorBasci, Semih
dc.contributor.authorCakar, Merih Kizil
dc.date.accessioned2021-12-10T10:05:56Z
dc.date.available2021-12-10T10:05:56Z
dc.identifier.citationUlu B. U. , Dal M. S. , Hindilerden I. Y. , Akay O. M. , MEHTAP Ö., Buyukkurt N., Hindilerden F., Gunes A. K. , Yigenoglu T. N. , Basci S., et al., "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients", JOURNAL OF CHEMOTHERAPY, 2021
dc.identifier.issn1120-009X
dc.identifier.othervv_1032021
dc.identifier.otherav_2862fd7f-37ef-4f24-81be-85c5d51c7f6a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/169175
dc.identifier.urihttps://doi.org/10.1080/1120009x.2021.1976912
dc.description.abstractThe prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m(2) B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
dc.language.isoeng
dc.subjectPathology and Forensic Medicine
dc.subjectPharmacology (medical)
dc.subjectBiochemistry (medical)
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectInfectious Diseases
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectOncology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPATOLOJİ
dc.subjectBiyoloji ve Biyokimya
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectPatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectGeneral Immunology and Microbiology
dc.subjectPharmacology
dc.subjectImmunology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectHistology
dc.titleBrentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
dc.typeMakale
dc.relation.journalJOURNAL OF CHEMOTHERAPY
dc.contributor.departmentUniversity of Health Sciences Turkey , ,
dc.contributor.firstauthorID2735913


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster